New cholesterol drug tested in taiwan: hope for Statin-Intolerant patients
NCT ID NCT06925100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested bempedoic acid, a new cholesterol-lowering drug, in 180 Taiwanese adults with high cholesterol or mixed lipid problems. Participants took a 180 mg tablet daily for 12 weeks. The goal was to see how much it lowered 'bad' LDL cholesterol and whether it was safe, especially for those who cannot take statins. Results could help doctors manage cholesterol more effectively in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bempedoic acid
- What this could lead to
- If successful, this could confirm that bempedoic acid works well and safely for lowering cholesterol in Taiwanese patients, offering a new option for those who cannot take statins.
- What could go wrong
- This is a small, short-term study (12 weeks) with no comparison group, so results may not prove long-term benefits or apply to all patients. Side effects are possible, though muscle problems are less likely than with statins.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Far Eastern Memorial Hospital
New Taipei City, 220, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807, Taiwan
-
Linkou Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.